Boston Therapeutics today announced positive results of a clinical study of its SUGARDOWN® product, a non-systemic chewable dietary supplement tablet designed to reduce the spike in post-meal blood glucose. SUGARDOWN is designed to be taken before meals to block the action of carbohydrate-hydrolyzing enzymes, which break down carbohydrates into glucose and release them into the bloodstream.
Conducted at the University of Sydney in Australia, the clinical trial showed that the post-meal incremental area under the curve (iAUC) for glucose and insulin were significantly lower following consumption of SUGARDOWN prior to a high carbohydrate meal of rice in a dose-dependent manner.
SUGARDOWN was tested at two doses in 10 healthy, non-smoking subjects, resulting in a reduction of up to 61 percent in post-meal elevation of blood glucose compared with the rice consumed alone. On average, there was a 32 percent reduction in the post-meal iAUC for glucose and a 24 percent reduction in post-meal insulin.
“These study results demonstrate that SUGARDOWN dietary supplement tablets can have a significant effect in reducing post-meal glucose and insulin responses,” David Platt, Ph.D., CEO of Boston Therapeutics stated in the press release. “Such a nutritional approach may be valuable in the management of blood sugar and could enhance the role of functional dietary supplements as part of a diabetes management plan.”
Boston Therapeutics reports that no severe adverse effects were reported or observed during the study.
For more information visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment